Influence of Mammography Volume on Radiologists' Performance: Results from BreastScreen Norway.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 29 5 2019
medline: 27 2 2020
entrez: 29 5 2019
Statut: ppublish

Résumé

Background Several European screening mammography programs that use independent double reading with consensus recommend an annual minimum reading volume of 5000 mammograms per radiologist. This recommendation is based only on expert opinion, and the influence of reading volume on performance in such programs is unknown. Purpose To examine the influence of annual and cumulative reading volume on radiologists' reading performance for digital mammography in a screening program that uses independent double reading with consensus. Materials and Methods This retrospective study included data from digital mammographic examinations in BreastScreen Norway obtained from 2006 to 2016. Multilevel mixed-effects models were used to determine how sensitivity, rate of screening-detected breast cancer (SDC), and false-positive rate (FPR) before and after consensus meeting related to annual and cumulative reading volume. Results The study included 2 373 433 readings performed by 121 radiologists. The median annual reading volume ranged from 153 to 19 500 mammograms, and the median cumulative reading volume was 30 566 mammograms. Sensitivity and SDC rate were relatively stable at 87% to 90% and 4.9 to 4.7 per 1000 readings (0.49% and 0.47%), respectively, between 100 and 10 000 annual readings and at 88% to 89% and 4.8 to 4.9 per 1000 readings (0.48% and 0.49%) between 500 and 100 000 cumulative readings. There was a decreasing trend with higher annual volumes (

Identifiants

pubmed: 31135295
doi: 10.1148/radiol.2019182684
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-296

Commentaires et corrections

Type : CommentIn

Auteurs

Solveig Roth Hoff (SR)

From the Department of Radiology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Åsehaugen 5, 6017 Ålesund, Norway, Ålesund, Norway; Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Trondheim, Norway (S.R.H.); Department of Research and Innovation, Møre og Romsdal Hospital Trust, Ålesund, Norway; Cancer Registry of Norway, Oslo, Norway (T.A.M.); Department of Radiology, University of Washington School of Medicine; Department of Health Services, University of Washington School of Public Health, Seattle, Washington (C.I.L.); Cancer Registry of Norway, Oslo, Norway (S.H.); and Department of Health Science, Oslo Metropolitan University, Oslo, Norway (S.H.).

Tor-Åge Myklebust (TÅ)

From the Department of Radiology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Åsehaugen 5, 6017 Ålesund, Norway, Ålesund, Norway; Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Trondheim, Norway (S.R.H.); Department of Research and Innovation, Møre og Romsdal Hospital Trust, Ålesund, Norway; Cancer Registry of Norway, Oslo, Norway (T.A.M.); Department of Radiology, University of Washington School of Medicine; Department of Health Services, University of Washington School of Public Health, Seattle, Washington (C.I.L.); Cancer Registry of Norway, Oslo, Norway (S.H.); and Department of Health Science, Oslo Metropolitan University, Oslo, Norway (S.H.).

Christoph I Lee (CI)

From the Department of Radiology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Åsehaugen 5, 6017 Ålesund, Norway, Ålesund, Norway; Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Trondheim, Norway (S.R.H.); Department of Research and Innovation, Møre og Romsdal Hospital Trust, Ålesund, Norway; Cancer Registry of Norway, Oslo, Norway (T.A.M.); Department of Radiology, University of Washington School of Medicine; Department of Health Services, University of Washington School of Public Health, Seattle, Washington (C.I.L.); Cancer Registry of Norway, Oslo, Norway (S.H.); and Department of Health Science, Oslo Metropolitan University, Oslo, Norway (S.H.).

Solveig Hofvind (S)

From the Department of Radiology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Åsehaugen 5, 6017 Ålesund, Norway, Ålesund, Norway; Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Trondheim, Norway (S.R.H.); Department of Research and Innovation, Møre og Romsdal Hospital Trust, Ålesund, Norway; Cancer Registry of Norway, Oslo, Norway (T.A.M.); Department of Radiology, University of Washington School of Medicine; Department of Health Services, University of Washington School of Public Health, Seattle, Washington (C.I.L.); Cancer Registry of Norway, Oslo, Norway (S.H.); and Department of Health Science, Oslo Metropolitan University, Oslo, Norway (S.H.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH